Refractory pyoderma gangrenosum associated with rheumatoid arthritis successfully treated with upadacitinib. Comments on: "JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum".

Refractory pyoderma gangrenosum associated with rheumatoid arthritis successfully treated with upadacitinib. A significant number of cytokines rely on JAK1 and JAK2, while the dependency of cytokines on JAK3 is more limited.[6] IL-6 activates intracellular signaling pathways primarily involving JAK1 and STAT3. The successful treatment of these patients with JAK inhibitors suggests the interference on the inflammatory signaling mediated by IL-6. [Extracted from the article]